CD4 and neoplasm: The remarkable breadth of the virus-specific CD4+ T-cell response and the fact that classical PTLD, like LCL, express all latent antigens of EBV and contain lytically infected cells expressing ∼80 lytic cycle proteins [3], [22], raises the question, whether the different CD4+ T-cell specificities are equally tumor-protective or whether some have non-redundant functions in tumor control and, therefore, should be enriched in T-cell preparations for adoptive therapy.